Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 646.87

+0.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Felix B who wrote (3121)	10/27/2020 3:13:54 AM
From: Miljenko Zuanic	Read Replies (1) of 3557

Yes, in hospitalized patients (with high viral titer) it is harder to generate benefit...but Ebola (blood borne virus) show opposite. On 3Q Lucentis sale, it did well in US (392 F, Roche) and ex-US ($515M, Novartis). Indicate Eylea will do VERY WELL, giving COVID-19 effects. Dupi also strong in 3Q. Ready for positive surprise.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next